Molecular Weight(MW): 1079.11
Vinorelbine Tartrate is a semi-synthetic vinca alkaloid, and inhibits mitosis through interaction with tubulin.
2 Customer Reviews
JQ1 and chemotherapeutics (vinorelbine, docetaxel, cisplatin and carboplatin) cooperate to induce apoptosis. MDA-MB-231 and HS578T were exposed to drugs alone and in combination with JQ1, at the indicated doses. Apoptosis was examined after 72 hours of treatment by flow cytometry using Annexin V/ PI staining as previously described.
Mol Cancer Ther, 2016, 15(8):1823-33.. Vinorelbine Tartrate purchased from Selleck.
Activity of vinorelbine in NSCLC cell lines in cell viability assay. Activity of vinorelbine NCI-H23, NCI-H460, and NCC44 cell lines in a Cell Titer Glo cell viability assay. Cells were treated with increasing drug concentrations from 0-10000 nM. The data are plotted as the mean % of control cells against the corresponding drug concentration.
Cynthia Bernia from McGill University. Vinorelbine Tartrate purchased from Selleck.
Purity & Quality Control
Choose Selective Microtubule Associated Inhibitors
|Description||Vinorelbine Tartrate is a semi-synthetic vinca alkaloid, and inhibits mitosis through interaction with tubulin.|
|Features||A semi-synthetic vinca alkaloid as an anti-mitotic chemotherapy drug.|
Vinorelbine inhibits microtubule assembly by inducing tubulin aggregation into spirals and paracrystals.  Vinorelbine shows potent antiproliferative activity against a series of tumor cells, including human melanoma, non-small-cell lung cancer, breast cancer, etc. 
|In vivo||In vivo, Vinorelbine also shows antitumour activity against a series of subcutaneously-implanted human tumour xenografts. |
-  Fellous A, et al. Semin Oncol. 1989, 16(2 Suppl 4), 9-14.
-  Photiou A, et al. J Cancer Res Clin Oncol. 1992, 118(4), 249-254.
-  Zhou YT, et al. Asian Pac J Cancer Prev. 2013, 14(8), 4635-4639.
|In vitro||DMSO||100 mg/mL (92.66 mM)|
|Water||100 mg/mL warmed (92.66 mM)|
|Ethanol||100 mg/mL warmed (92.66 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT03423849||Not yet recruiting||Breast Cancer|Chemotherapy Effect|Disease-free Survival||Zhiyong Yu|Shandong Cancer Hospital and Institute||February 8 2018||Phase 2|Phase 3|
|NCT03656393||Recruiting||NSCLC|EGFR||Shenzhen People''s Hospital||August 31 2018||Phase 3|
|NCT02486718||Recruiting||Non-Small Cell Lung Cancer||Hoffmann-La Roche||October 31 2015||Phase 3|
|NCT03358004||Recruiting||Triple Negative Breast Cancer||Mario Negri Institute for Pharmacological Research||October 30 2017||Phase 2|
|NCT02610140||Active not recruiting||Mesothelioma||Bayer|ImmunoGen and MorphoSys||December 3 2015||Phase 2|
|NCT03393741||Recruiting||Breast Cancer|Breast Neoplasms||University of Wisconsin Madison|National Cancer Institute (NCI)||January 29 2018||--|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.